The drug’s pink coloring can fade over the course of its two-year shelf life, which can be confusing to patients. The FDA is requiring BioDelivery Sciences International to make formulation changes in Onsolis to prevent the color change over time. There are no safety issues noted with the drug.
Packages of Onsolis currently on shelves can still be used for pain treatment in cancer patients, but until the BDSI complies with the FDA’s manufacturing requirement, no new product will be made or shipped.
Related Articles on Pain Management:
5 Pain Management Physicians Discuss Urine Drug Testing
Physical Therapy Center Launches New Patient Education Website
Osteoarthritis Painkillers May Resume Trials Despite Joint Damage Risks
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
